Indicated for the symptoms of allergic rhinitis and urticaria.
Each film-coated tablet contains: Active ingredient: Desloratadine 5 mg
Excipients: Microcrystalline cellulose, colloidal silicon dioxide, calcium hydrogen phosphate, corn starch, talc, magnesium stearate, Opadry II Blue 31F205006 (purified water, lactose monohydrate, hypromellose, titanium dioxide, propylene glycol).
Relief of symptoms of allergic rhinitis (e.g., nasal discharge, nasal irritation and congestion, eye irritation and redness, tearing, throat irritation, cough) and urticaria (e.g., skin irritation, swelling, and redness).
For intermittent allergic rhinitis (symptoms present less than 4 days per week or less than 4 weeks per year), Aldesi can be used during symptom periods. Treatment may be stopped once symptoms disappear and resumed if symptoms reoccur.
For persistent allergic rhinitis (symptoms present more than 4 weeks per year or more than 4 days per week), long-term use during allergen exposure is recommended.
Adults and adolescents (12 years and older): 1 tablet once daily, independent of food intake.
Use with caution in patients with severe renal impairment. No data available for use in patients with liver impairment or children under 12 years. No specific studies in elderly patients.
Hallucinations, dizziness, drowsiness, psychomotor agitation, tachycardia, palpitations, abdominal pain, nausea, vomiting, dyspepsia, diarrhea, increased liver enzymes and bilirubin, hepatitis, muscle pain, anaphylaxis, angioneurotic edema, coughing, itching, rash, swelling.
Hypersensitivity to desloratadine, any component of the tablet, or loratadine.
No interactions observed with erythromycin or ketoconazole. Desloratadine does not potentiate alcohol’s negative effects. Possible interactions with oral contraceptives; alternative contraception is recommended during treatment.
Safety and efficacy in children under 12 years not established.
Not for use in patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Use cautiously in severe renal impairment.
Contains 1.8 mg lactose monohydrate; consider in diabetic patients.
Contains propylene glycol, but not in amounts expected to cause side effects.
Insufficient data in pregnant women; use not recommended during pregnancy. Desloratadine is excreted in breast milk; contraindicated during lactation.
Does not affect the ability to drive or operate machinery, but drowsiness may rarely occur.
Standard measures to eliminate any unabsorbed drug should be taken. Symptomatic and supportive treatment is recommended. Desloratadine is not removed by hemodialysis. Unknown if removed by peritoneal dialysis.
Store in original packaging, out of reach of children, at temperatures not exceeding 25°C.
